VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Male participants between 18 and 40 years-old      │ Male participants between 18 and 40 years-old      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent signed by the participant │ Written informed consent signed by the participant │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lifetime personal history of diagnosis of major    │ Lifetime personal history of diagnosis of major    │     100 │
│ depressive disorder according to the DSM-V         │ depressive disorder according to the DSM-V         │         │
│ (American Psychiatric Association, 2013) using the │ (American Psychiatric Association, 2013) using the │         │
│ Structured Clinical Interview for DSM-V Axis I     │ Structured Clinical Interview for DSM-V Axis I     │         │
│ Disorders, Research Version, Non-patient Edition   │ Disorders, Research Version, Non-patient Edition   │         │
│ (SCID-5-RV for DSM-V; First et al., 2015)          │ (SCID-5-RV for DSM-V; First et al., 2015)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A history of suicidal ideation and behaviour,      │ A history of suicidal ideation and behaviour,      │     100 │
│ including self-harm and/or harm to others          │ including self-harm and/or harm to others          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A history of substance abuse and/or dependence     │ A history of substance abuse and/or dependence     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A positive drug screen for illicit drugs           │ A positive drug screen for illicit drugs           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Substantial alcohol use                            │ Substantial alcohol use                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of Monoamine Oxidase Inhibitors        │ Current use of Monoamine Oxidase Inhibitors        │     100 │
│ (MAOIs), including the antibiotic linezolid and    │ (MAOIs), including the antibiotic linezolid and    │         │
│ the thiazine dye methylthioninium chloride         │ the thiazine dye methylthioninium chloride         │         │
│ (methylene blue)                                   │ (methylene blue)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of serotonin-precursors (such as       │ Current use of serotonin-precursors (such as       │     100 │
│ L-tryptophan, oxitriptan)                          │ L-tryptophan, oxitriptan)                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of serotonergic drugs (triptans,       │ Current use of serotonergic drugs (triptans,       │     100 │
│ certain tricyclic antidepressants, lithium,        │ certain tricyclic antidepressants, lithium,        │         │
│ tramadol, St. John's Wort)                         │ tramadol, St. John's Wort)                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant use of NSAIDS, ASA, and other          │ Concomitant use of NSAIDS, ASA, and other          │     100 │
│ anticoagulants                                     │ anticoagulants                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of Thioridazine                        │ Current use of Thioridazine                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of CYP1A2 Inhibitors                   │ Current use of CYP1A2 Inhibitors                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of Triptans (5HT1 Agonists)            │ Current use of Triptans (5HT1 Agonists)            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Blood pressure greater than 140/90 and/or a pulse  │ Blood pressure greater than 140/90 and/or a pulse  │     100 │
│ rate greater than 90 bpm                           │ rate greater than 90 bpm                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Recent history of myocardial infarction,           │ Recent history of myocardial infarction,           │     100 │
│ cerebrovascular accident, cardiac arrhythmias, or  │ cerebrovascular accident, cardiac arrhythmias, or  │         │
│ unstable heart disease                             │ unstable heart disease                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of significant physical illness           │ Evidence of significant physical illness           │     100 │
│ contraindicating the use of levomilnacipran and    │ contraindicating the use of levomilnacipran and    │         │
│ duloxetine found on the physical exam or in the    │ duloxetine found on the physical exam or in the    │         │
│ laboratory data obtained during the first week of  │ laboratory data obtained during the first week of  │         │
│ the study                                          │ the study                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of medication that may affect voiding  │ Current use of medication that may affect voiding  │     100 │
│ (ie- anticholinergics)                             │ (ie- anticholinergics)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of obstructive urinary disorders and       │ History of obstructive urinary disorders and       │     100 │
│ dysuria, prostatic hypertrophy, prostatitis, and   │ dysuria, prostatic hypertrophy, prostatitis, and   │         │
│ other lower urinary tract obstructive disorders    │ other lower urinary tract obstructive disorders    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of Stevens-Johnson Syndrome and Erythema   │ History of Stevens-Johnson Syndrome and Erythema   │     100 │
│ multiforme                                         │ multiforme                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diabetes Type I and II                             │ Diabetes Type I and II                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fructose intolerance, glucose-galactose            │ Fructose intolerance, glucose-galactose            │     100 │
│ malabsorption or sucrose-isomaltase insufficiency  │ malabsorption or sucrose-isomaltase insufficiency  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic Impairment                                 │ Hepatic Impairment                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled narrow-angle glaucoma                 │ Uncontrolled narrow-angle glaucoma                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe renal impairment                            │ Severe renal impairment                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of seizure disorder                        │ History of seizure disorder                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anatomically narrow ocular angles                  │ Anatomically narrow ocular angles                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Osteoporosis or major risk for bone fractures      │ Osteoporosis or major risk for bone fractures      │     100 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                 │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════╪═════════╡
│ Must be MALE                      │ Substantial alcohol use                       │      29 │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Male participants between 18 and 40 years-old │      41 │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 40 Years │ Male participants between 18 and 40 years-old │      44 │
╘═══════════════════════════════════╧═══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 94.0
OverAll Ratio: 96.0
